Technical Analysis for ATXI - Avenue Therapeutics, Inc.

Grade Last Price % Change Price Change
D 0.16 1.59% 0.00
ATXI closed up 1.59 percent on Monday, March 18, 2024, on 28 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Mar 28
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Resistance Bearish 1.59%
50 DMA Resistance Bearish 1.59%
Wide Bands Range Expansion 1.59%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 15 hours ago
Possible NR7 about 15 hours ago
Possible Inside Day about 15 hours ago
Up 5% about 19 hours ago
Rose Above 20 DMA about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avenue Therapeutics, Inc. Description

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Chemical Compounds Opioids Chloride Analgesics Amines Neurochemistry Hepatotoxins Pharmacokinetics Paracetamol Nonsteroidal Anti Inflammatory Drug

Is ATXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.36
52 Week Low 0.1125
Average Volume 2,643,575
200-Day Moving Average 0.56
50-Day Moving Average 0.15
20-Day Moving Average 0.16
10-Day Moving Average 0.17
Average True Range 0.02
RSI (14) 50.50
ADX 18.46
+DI 24.34
-DI 14.96
Chandelier Exit (Long, 3 ATRs) 0.15
Chandelier Exit (Short, 3 ATRs) 0.19
Upper Bollinger Bands 0.18
Lower Bollinger Band 0.13
Percent B (%b) 0.52
BandWidth 31.86
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram -0.0003
Fundamentals Value
Market Cap 5.97 Million
Num Shares 37.3 Million
EPS -2.62
Price-to-Earnings (P/E) Ratio -0.06
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.17
Resistance 3 (R3) 0.17 0.17 0.17
Resistance 2 (R2) 0.17 0.17 0.17 0.17
Resistance 1 (R1) 0.16 0.17 0.16 0.16 0.17
Pivot Point 0.16 0.16 0.16 0.16 0.16
Support 1 (S1) 0.16 0.16 0.16 0.16 0.15
Support 2 (S2) 0.15 0.16 0.15 0.15
Support 3 (S3) 0.15 0.15 0.15
Support 4 (S4) 0.15